Cargando…
Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended
BACKGROUND: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) ended in 2002, but it is important to study its long-term outcomes during the posttrial period by incorporating posttrial antihypertensive medication uses in the analysis. PURPOSES: The primary aim is to...
Autores principales: | Du, Xianglin L., Simpson, Lara M., Tandy, Brian C., Bettencourt, Judy, Davis, Barry R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677412/ https://www.ncbi.nlm.nih.gov/pubmed/34925915 http://dx.doi.org/10.1155/2021/2261144 |
Ejemplares similares
-
Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker
por: Du, Xianglin L., et al.
Publicado: (2021) -
The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT–Medicare linked data
por: Du, Xianglin L., et al.
Publicado: (2023) -
Risk of Developing Alzheimer’s Disease and Related Dementias in ALLHAT Trial Participants Receiving Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker with 18 Years of Follow-Up
por: Du, Xianglin L., et al.
Publicado: (2022) -
Antihypertensive Drug Effects on Renal Function and Myocardial Infarction and Implications of the ALLHAT Study Results
por: Curtiss, Frederic R.
Publicado: (2003) -
Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings
por: Boyett, Brent, et al.
Publicado: (2023)